Mabion S.A. (MAB.WA)
PLN 10.28
(-1.72%)
PLN 10.28
(-1.72%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 2.55 PLN | 77.08% |
| 2022 | 1.44 PLN | 1100.0% |
| 2021 | 0.12 PLN | 102.88% |
| 2020 | -4.17 PLN | 11.65% |
| 2019 | -4.72 PLN | 10.27% |
| 2018 | -5.26 PLN | -7.13% |
| 2017 | -4.91 PLN | -1.45% |
| 2016 | -4.84 PLN | -1052.38% |
| 2015 | -0.42 PLN | 4.55% |
| 2014 | -0.44 PLN | 10.2% |
| 2013 | -0.49 PLN | -22.5% |
| 2012 | -0.40 PLN | -42.86% |
| 2011 | -0.28 PLN | -509.96% |
| 2010 | 0.07 PLN | 243.49% |
| 2009 | -0.05 PLN | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.64 PLN | -41.28% |
| 2024 Q3 | -1.01 PLN | -257.81% |
| 2024 Q1 | 1.09 PLN | 1462.5% |
| 2023 Q3 | 0.67 PLN | -28.72% |
| 2023 Q2 | 0.94 PLN | -7.84% |
| 2023 FY | - PLN | 77.08% |
| 2023 Q1 | 1.02 PLN | 5.15% |
| 2023 Q4 | -0.08 PLN | -111.94% |
| 2022 Q3 | -0.20 PLN | -162.5% |
| 2022 Q1 | 0.46 PLN | -70.89% |
| 2022 FY | - PLN | 1100.0% |
| 2022 Q4 | 0.97 PLN | 585.0% |
| 2022 Q2 | 0.32 PLN | -30.43% |
| 2021 FY | - PLN | 102.88% |
| 2021 Q4 | 1.58 PLN | 262.89% |
| 2021 Q1 | -1.24 PLN | -6.9% |
| 2021 Q3 | -0.97 PLN | -546.67% |
| 2021 Q2 | -0.15 PLN | 87.9% |
| 2020 Q1 | -1.45 PLN | -29.46% |
| 2020 Q4 | -1.16 PLN | -75.76% |
| 2020 FY | - PLN | 11.65% |
| 2020 Q3 | -0.66 PLN | 17.5% |
| 2020 Q2 | -0.80 PLN | 44.83% |
| 2019 Q4 | -1.12 PLN | 8.2% |
| 2019 FY | - PLN | 10.27% |
| 2019 Q1 | -1.09 PLN | 23.24% |
| 2019 Q2 | -1.22 PLN | -11.93% |
| 2019 Q3 | -1.22 PLN | 0.0% |
| 2018 Q1 | -1.22 PLN | 25.61% |
| 2018 FY | - PLN | -7.13% |
| 2018 Q3 | -0.95 PLN | 53.66% |
| 2018 Q2 | -2.05 PLN | -68.03% |
| 2018 Q4 | -1.42 PLN | -49.47% |
| 2017 Q4 | -1.64 PLN | -46.43% |
| 2017 Q3 | -1.12 PLN | -5.66% |
| 2017 Q2 | -1.06 PLN | 3.64% |
| 2017 Q1 | -1.10 PLN | 74.71% |
| 2017 FY | - PLN | -1.45% |
| 2016 Q2 | -1.21 PLN | -505.0% |
| 2016 Q1 | -0.20 PLN | -575.68% |
| 2016 FY | - PLN | -1052.38% |
| 2016 Q4 | -4.35 PLN | -2618.75% |
| 2016 Q3 | -0.16 PLN | 86.78% |
| 2015 Q1 | -0.15 PLN | 16.67% |
| 2015 Q2 | -0.06 PLN | 57.4% |
| 2015 FY | - PLN | 4.55% |
| 2015 Q4 | -0.03 PLN | 87.67% |
| 2015 Q3 | -0.24 PLN | -275.59% |
| 2014 FY | - PLN | 10.2% |
| 2014 Q4 | -0.18 PLN | -38.46% |
| 2014 Q3 | -0.13 PLN | 0.0% |
| 2014 Q2 | -0.13 PLN | -46.89% |
| 2014 Q1 | -0.09 PLN | 50.83% |
| 2013 Q1 | -0.06 PLN | 68.5% |
| 2013 Q3 | -0.11 PLN | 52.17% |
| 2013 Q4 | -0.18 PLN | -63.64% |
| 2013 Q2 | -0.23 PLN | -265.08% |
| 2013 FY | - PLN | -22.5% |
| 2012 Q2 | -0.10 PLN | -83.49% |
| 2012 Q4 | -0.20 PLN | -262.32% |
| 2012 FY | - PLN | -42.86% |
| 2012 Q1 | -0.05 PLN | 0.0% |
| 2012 Q3 | -0.06 PLN | 44.8% |
| 2011 FY | - PLN | -509.96% |
| 2010 FY | - PLN | 243.49% |
| 2009 FY | - PLN | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Bioceltix S.A. | -3.49 PLN | 173.066% |
| BIOTON S.A. | 0.03 PLN | -9522.642% |
| Captor Therapeutics Spolka Akcyjna | -15.19 PLN | 116.787% |
| Molecure S.A. | -1.09 PLN | 333.945% |
| NanoGroup S.A. | -0.39 PLN | 753.846% |
| Pharmena S.A. | 2.60 PLN | 1.923% |
| Poltreg S.A. | -2.91 PLN | 187.629% |
| Pure Biologics Spólka Akcyjna | -11.19 PLN | 122.788% |
| Ryvu Therapeutics S.A. | -4.02 PLN | 163.433% |
| Synthaverse S.A. | 0.07 PLN | -3666.617% |
| Urteste S.A. | -4.32 PLN | 159.028% |